Oral Thin Films – Tailoring Therapy Need
Sponsored by: LTS Lohmann Therapy Systems
- Oral Drugs
- Drug Delivery
Date: 29 November
Time: 2PM London/9AM New York
Oral Thin Films - a versatile LTS technology that offers a broad range of drug loading, PK profile modulation and patient benefits. New developments and opportunities in the OTF field bring significant benefits for new therapy approached.
Oral drug delivery technologies form an important part of the pharmaceutical industry representing the largest share of the overall market. In particular oral transmucosal drug delivery systems have recently gained a lot of attention. One of the key driving factors is the preference for non- invasive routes of drug delivery. Although oral thin films have been available in the forms of breath freshening strips, vitamin strips and other over-the-counter products for the past two decades, pharmaceutical companies have recently directed their focus towards formulating prescription products into oral thin films.
Oral mucosal drug delivery provide several advantages over traditional oral drug delivery methods such as the ease of self-administration, increased bioavailability, rapid onset of action, no water required and improved patient compliance. Oral thin films provide fast accurate dosing and are expected to increase compliance, especially among elders and children. Given the specific advantages offered by these films and their ability to overcome the current unmet needs, the future holds significant potential.
Dr. Marco Emgenbroich,
Corporate Senior Director Head of Pharmaceutical Development
Dr. Marco Emgenbroich studied chemistry at the Heinrich-Heine University of Düsseldorf in Germany. He then joined a graduate school program on molecular physiology for PhD candidates and in early 2003 received his doctorate degree in organic and macromolecular chemistry.
After a postdoctoral fellowship in the biomedical applications of polymer matrices, Marco began his industrial career in the biotech field, where he worked on delivery of peptides and protein drug for parenteral applications.
Early in 2011 he joined the R&D department of LTS Lohmann Therapy Systems in Germany, where he was responsible for the late stage development program and global launch of the Neupro patch.
Since 2015, Marco has been responsible for pharmaceutical development teams working on collaboration projects in the area of transdermal therapeutic systems and oral thin films.
Key Learning Objectives
- This webinar will show the components and science of OTFs and how it can be used to provide a genuine alternative to current drug delivery methods – and be considered as a genuine alternative dosage form.
- Features and benefits of using OTFs to address disease areas will be discussed, highlighting the market potential and increased market share associated with the development of the product.
- Formulation Scientist
- Drug Delivery Scientists
- R&D Scientist
- Formulation Pharmacist
- Heads of Research and Development
- Head of Pharmaceutical Technology
- Director of Formulation
- Director Formulation Development
- Head of Product Development
- Heads of Innovation Technology